| Full Name | Dina Kogan |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 24 Years |
| Location | 555 N 30th St, Omaha, Nebraska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154311785 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 036109386 (Illinois) | Secondary |
| 207L00000X | Anesthesiology | 23795 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Nebraska Medical Center | Omaha, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unmc Physicians | 6002728391 | 1320 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
The first investigational transplant of a genetically engineered, nonhuman kidney to a human body was recently completed at NYU Langone Health—marking a major step forward in potentially utilizing an alternative supply of organs for people facing life-threatening disease.
In the current issue of Family Medicine and Community Health (Volume 6,Number 3, 2018, pp.104-114; DOI:https://doi.org/10.15212/FMCH.2018.0109, researchers Ajibola A. Ishola, Chisom C. Obasi and Ismail T. Sholuke of the Department of Psychology, University of Ibadan, Ibadan, Nigeria, describes how having a baby is often marked by disturbance in mood, and the birth of a premature baby can put mothers at greater risk of psychological distress than the birth of a full-term baby.
NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch eTNS System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013.
Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.
› Verified 2 days ago
| Entity Name | Unmc Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417912114 PECOS PAC ID: 6002728391 Enrollment ID: O20031104000664 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
The first investigational transplant of a genetically engineered, nonhuman kidney to a human body was recently completed at NYU Langone Health—marking a major step forward in potentially utilizing an alternative supply of organs for people facing life-threatening disease.
In the current issue of Family Medicine and Community Health (Volume 6,Number 3, 2018, pp.104-114; DOI:https://doi.org/10.15212/FMCH.2018.0109, researchers Ajibola A. Ishola, Chisom C. Obasi and Ismail T. Sholuke of the Department of Psychology, University of Ibadan, Ibadan, Nigeria, describes how having a baby is often marked by disturbance in mood, and the birth of a premature baby can put mothers at greater risk of psychological distress than the birth of a full-term baby.
NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch eTNS System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013.
Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.
› Verified 2 days ago
| Entity Name | Father Flanagans Boys Home |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295821825 PECOS PAC ID: 9638165400 Enrollment ID: O20040426000622 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
The first investigational transplant of a genetically engineered, nonhuman kidney to a human body was recently completed at NYU Langone Health—marking a major step forward in potentially utilizing an alternative supply of organs for people facing life-threatening disease.
In the current issue of Family Medicine and Community Health (Volume 6,Number 3, 2018, pp.104-114; DOI:https://doi.org/10.15212/FMCH.2018.0109, researchers Ajibola A. Ishola, Chisom C. Obasi and Ismail T. Sholuke of the Department of Psychology, University of Ibadan, Ibadan, Nigeria, describes how having a baby is often marked by disturbance in mood, and the birth of a premature baby can put mothers at greater risk of psychological distress than the birth of a full-term baby.
NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch eTNS System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013.
Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dina Kogan, MD 16165 Bedford Ave, Omaha, NE 68116-6434 Ph: (402) 763-8950 | Dina Kogan, MD 555 N 30th St, Omaha, NE 68131-2136 Ph: (402) 498-6509 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
The first investigational transplant of a genetically engineered, nonhuman kidney to a human body was recently completed at NYU Langone Health—marking a major step forward in potentially utilizing an alternative supply of organs for people facing life-threatening disease.
In the current issue of Family Medicine and Community Health (Volume 6,Number 3, 2018, pp.104-114; DOI:https://doi.org/10.15212/FMCH.2018.0109, researchers Ajibola A. Ishola, Chisom C. Obasi and Ismail T. Sholuke of the Department of Psychology, University of Ibadan, Ibadan, Nigeria, describes how having a baby is often marked by disturbance in mood, and the birth of a premature baby can put mothers at greater risk of psychological distress than the birth of a full-term baby.
NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch eTNS System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013.
Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.
› Verified 2 days ago
Stephanie Franco, CRNA Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6901 N 72nd St, Omaha, NE 68122 Phone: 402-572-2121 | |
Dr. Joseph M Kalamaja, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: Emile 42nd St, Omaha, NE 68198 Phone: 402-559-4081 Fax: 402-559-7372 | |
Wesley K Hubka, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7822 Davenport St, Omaha, NE 68114 Phone: 402-391-4855 Fax: 402-391-6818 | |
Dr. Cam E Enarson, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2500 California Plz, Omaha, NE 68178 Phone: 402-280-5823 | |
Dr. Kimberly A Hanson, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: Children's Hospital - Anesthesiology, 8200 Dodge Street, Omaha, NE 68114 Phone: 402-955-4303 Fax: 402-955-4300 | |
Marvin Graves Henderson, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 6901 N 72 Street, Omaha, NE 68122 Phone: 402-778-9738 Fax: 402-334-2849 | |
John Ashton Heckathorn Ii, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7500 Mercy Rd Ste 1355, Omaha, NE 68124 Phone: 402-717-4866 |